Exploration of Targeted Anti-tumor Therapy

Home
/
Exploration of Targeted Anti-tumor Therapy
/
Articles
/
T1

From: Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors

Table 1

Key clinical trials with ibrutinib in CLL

Name	Phase	Population	Response	Ref
N/A	IB/II	R/R^b	71% ORR^c by standard response criteria. Additional 18% partial response with persistent lymphocytosis	[62]
Resonate	III	R/R	Demonstrated that ibrutinib was superior to ofatumumab for response rate, PFS^d and OS^e	[63]
N/A	I/IB	TN^f ≥ 65 years	90% achieved objective response or partial response with persistent lymphocytosis	[64]
Resonate-2	III	TN ≥ 65 years	Demonstrated that ibrutinib was superior to chlorambucil for overall response rate, PFS and OS	[65]
Helios	III	R/R	Ibrutinib + bendamustine/rituximab superior to bendamustine/rituximab for PFS and OS	[66, 67]
Alliance A041202	III	TN ≥ 65 years	Ibrutinib superior to bendamustine + rituximab for PFS. No difference between ibrutinib or ibrutinib + rituximab for PFS	[68]
ECOG 1912	III	TN ≤ 70 years	Ibrutinib + rituximab superior to CIT for PFS and OS at interim analysis	[69]
iLLUMINATE	III	TN ≥ 65 years or < 65 years with coexisting conditions	Ibrutinib + obinutuzumab superior to chlorambucil + obinutuzumab for PFS	[70]

Return to article view

a

N/A: not applicable;

b

R/R: relapsed/refractory;

c

ORR: overall response rate;

d

PFS: progression-free survival;

e

OS: overall survival;

f

TN: treatment naïve